Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Study type
- Clinical guideline
- Study name
- ESMO RCC 2024
- Design
- ESMO Clinical Practice Guideline. Methodological details are not given in the PubMed record and should be taken from the full text of the guideline.
- Source
- Annals of Oncology · 2024
In plain words
This article is the clinical guideline of the European Society for Medical Oncology (ESMO) on diagnosing, treating and following up kidney (renal cell) cancer, and it was written to guide doctors. The exact treatment recommendations depend on each patient's situation. Be sure to talk with your treating doctor about choosing a treatment.
Study population
No abstract is available in the PubMed record. The title indicates that the subject is renal cell carcinoma. Details of the target population are in the full text of the guideline.
Endpoints
This is a clinical guideline, not a trial; no defined endpoint is given in the record.
Safety and side effects
No abstract is available in the record and no safety information is given. Details are in the full text of the guideline.
Clinical significance and place in guidelines
This guideline is one of the international references for the diagnosis, treatment and follow-up of renal cell carcinoma. The record has no abstract, so the recommendations, levels of evidence and changes from previous versions cannot be extracted from it. These should be checked in the full text and approved by an oncologist before publication.
Limitations
The PubMed record has no abstract and no specific recommendation is quoted on this card. The full text of the guideline must be reviewed to complete the recommendations and levels of evidence.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.